On Tuesday, Shares of Texas Instruments Inc. (NASDAQ:TXN), lost -3.14% to $46.34.
Texas Instruments Incorporated, Orbit Research and the American Printing House for the Blind (APH) recently unveiled the Orion TI-30XS MultiView Talking Scientific Calculator, the world’s first fully accessible multi-line scientific calculator, created for students who are visually impaired, and available for the forthcoming school year. Based on the popular TI-30XS Multiview™ scientific calculator from Texas Instruments, the Orion TI-30XS represents a breakthrough in Science, Technology, Engineering and Mathematics (STEM) education for students with vision impairment.
Recently, millions of scientific calculators are used in classrooms around the world and are an integral part of the high school math and science curriculum. However, the popularity and usefulness of scientific calculators has posed a challenge for students who are visually impaired since advanced models used in classrooms have not been accessible, until now. With the introduction of the Orion TI-30XS MultiView, visually impaired students now have access to the same technology as their peers as they tackle demanding subjects such as algebra, statistics and chemistry.
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing.
Shares of Southern Company (NYSE:SO), declined -2.30% to $42.41, during its last trading session.
Expanding on one of America’s largest renewable portfolios, Southern Company partner Southern Power recently declared the acquisition of a controlling interest in the 200-megawatt (MW) Tranquillity Solar Facility in California from Recurrent Energy, a partner of Canadian Solar Inc. One of North America’s largest solar developers, Recurrent Energy is constructing the facility and will retain the remaining interest in the project.
“Southern Company’s planned solar expansion is assisting diversify our energy mix while strengthening our industry leadership in solar,” said Southern Company Chairman, President and CEO Thomas A. Fanning. “We will continue to develop the right projects and develop innovative solutions as we shape America’s energy future.”
The project, which represents Southern Power and Recurrent Energy’s first partnership, is predictable to generate enough clean solar energy to power about 55,000 homes when accomplished, assisting California meet its ambitious carbon emission reduction aims.
With one of America’s most robust renewable generation portfolios, Southern Power has declared, attained or is constructing more than 1,300 MW of renewable ownership with 19 solar, wind and biomass projects, counting six solar projects in California. This facility adds further diversity and reliability to the Southern Company system’s generation mix of nuclear, 21st century coal, natural gas, renewables and energy efficiency.
The project is being constructed on 1,900 acres of land in Fresno County, California. Predictable to create about 500 construction jobs, the facility will comprise of more than 800,000 polycrystalline photovoltaic solar modules, mounted on tracking tables.
The Southern Company, together with its auxiliaries, operates as a public electric utility company. It is involved in the generation, transmission, and distribution of electricity through coal, nuclear, oil and gas, and hydro resources in the states of Alabama, Georgia, Florida, and Mississippi.
Finally, Wright Medical Group Inc. (NASDAQ:WMGI), ended its last trade with -0.65% loss, and closed at $22.92.
Wright Medical Group declared that its BioMimetic partner has received an approval order from the U.S. Food and Drug Administration (FDA) for its Premarket Approval Application (PMA) for AUGMENT® Bone Graft. The approval order indicates that FDA determined that AUGMENT® Bone Graft is safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications. Wright can now initiate commercial sale and distribution of AUGMENT® Bone Graft in the U.S.
Robert Palmisano, president and chief executive officer, stated, “The FDA approval of AUGMENT marks a capstone achievement that demonstrates the strength of our science and provides a breakthrough therapeutic option as an alternative to autograft in ankle and hindfoot fusion procedures. We will start commercial sale and distribution of AUGMENT in the U.S. and believe this product, in addition to the PDGF technology platform, will be important drivers of the long-term growth of our business for years to come.”
The Company continues to anticipate AUGMENT® revenue in the U.S. to be in the range of $10 million to $12 million in the first seven to eight months post-approval. The revenue ramp is predictable to build gradually during the first six months following the launch of the product as launch activities, such as review by hospital value analysis committees and physician education, are initiated. The company anticipates to start selling product in the U.S. in the next several weeks once inventory is moved into its U.S. distribution network.
Wright Medical Group, Inc., a specialty orthopaedic company, provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients lifestyles worldwide. The company offers products that are used primarily in foot and ankle repair, upper extremity products, and biologics products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
